Antimicrobial Agents and Chemotherapy · 2018 · 38 citations · 57 references
PharmacyPharmacologyPharmacotherapyAntimicrobial PharmacotherapyInfectious Disease PharmacotherapyTuberculosis ControlAntibacterial TherapyCarbapenem ResistanceTuberculosis CareTuberculosis Diagnostic TestingTuberculosis EpidemiologyTuberculosis PharmacotherapyCombination Therapy For TuberculosisDrug Resistance TestingExtensively Drug-resistant Tuberculosis TreatmentIn Vivo StudiesMycobacterium Tuberculosis InfectionPhenotypic Drug Susceptibility TestingSystematic Literature ReviewTuberculosis Drug Resistance
studies have been performed, including one prospective, two observational, and seven retrospective clinical studies to assess the effectiveness, safety, and tolerability of three different carbapenems (imipenem, meropenem, and ertapenem). We found no clear evidence at the present time to select one particular carbapenem among the different candidate compounds to design an effective M/XDR-TB regimen. Therefore, more clinical evidence and dose optimization substantiated by hollow-fiber infection studies are needed to support repurposing carbapenems for the treatment of M/XDR-TB.
57
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher, A. Liberati, Jennifer Tetzlaff et al. · BMJ · 2009 · 83.3K citations · Full text
Marie Lavollay, Michel Arthur, Martine Fourgeaud et al. · Journal of Bacteriology · 2008 · 348 citations